

## **Adhoc-News**

### **Marinomed Biotech AG enters into license agreement with Procter & Gamble on Carragelose® products**

**Korneuburg, Austria, 19 May 2022** – Marinomed Biotech AG (VSE:MARI), hereinafter referred to as "Marinomed", announces the execution of a license agreement with Procter & Gamble Company (NYSE: PG), hereinafter referred to as "P&G", for the United States of America regarding the Carragelose® products of Marinomed, which are protected by various patents that cover the use of iota-carrageenan for the treatment of diseases caused by or associated with an infection by a respiratory virus.

P&G will take the necessary steps to obtain regulatory approval for the commercialization of the Carragelose® products in the United States of America. Marinomed is responsible for the technology transfer, i.e., providing P&G with the data required for obtaining regulatory approval and the intellectual property rights (patents, know-how) in the form of a license for the commercialization of the Carragelose® products in the United States of America.

Under the terms of the agreement and depending on the achievement of specified regulatory and commercial milestones, Marinomed is eligible to receive milestone payments as well as royalties on Carragelose® sales in the United States of America.

+++ End of the ad hoc announcement +++

#### **For further inquiries contact:**

**Marinomed Biotech AG**

**Pascal Schmidt, CFO**

Hovengasse 25, 2100 Korneuburg, Austria

+43 2262 90300

Email: [ir@marinomed.com](mailto:ir@marinomed.com)

#### **Disclaimer**

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.